Understand total testosterone results, the EAU testing threshold and how SHBG, free testosterone and laboratory methods shape interpretation.
Total testosterone is the amount of testosterone in the blood, including testosterone attached to proteins and the portion that is unbound. A total testosterone test measures these portions together rather than reporting each separately.
UCSF Health distinguishes this measurement from a free testosterone test. Free testosterone refers to the unbound portion. Much of the testosterone circulating in blood is attached to sex hormone-binding globulin, usually shortened to SHBG.
This article is for informational purposes only and is not medical advice. A qualified clinician should interpret individual results and make diagnostic or treatment decisions.
Clinicians interpret total testosterone within a laboratory context, not as an isolated score. The European Association of Urology (EAU) notes differences in laboratory practices and the need to consider measurement methods when comparing results. That matters when a result sits near a decision threshold or when reports come from different laboratories.
A reference interval on a laboratory report and a clinical decision threshold serve different purposes. The interval provides the laboratory's comparison range for its result. A guideline threshold helps structure a clinical evaluation. Neither separates the protein-bound and free portions of testosterone.
In its framework for late-onset hypogonadism, the EAU recommends at least two separate measurements when total testosterone is below 12 nmol/L. It specifies morning fasting testing between 07:00 and 10:00. The recommendation concerns confirmation under defined testing conditions.
That threshold is not a complete lower-to-upper reference interval. It should not be read as a target that every man needs to reach. Biologically, the measurement remains the combined amount of bound and unbound testosterone in the blood sample.
Rather than treating a laboratory flag as a final conclusion, a useful discussion addresses the laboratory's interval and the clinician's decision threshold. Testostra's explanation of how reference intervals differ from diagnostic cutoffs provides related context.
The EAU recommends measuring SHBG and calculating free testosterone when indicated. This can be relevant when SHBG is altered or when a borderline total result leaves an interpretive question. The added assessment addresses the unbound fraction rather than simply repeating the combined measurement.
The method matters. The EAU describes equilibrium dialysis as the most accurate method for measuring free testosterone. It also supports calculating free testosterone using SHBG and albumin levels. These are distinct approaches that a clinician can discuss with the laboratory.
The guideline advises against direct free-testosterone immunoassays because they do not accurately estimate free testosterone. An assay is the laboratory method used to make a measurement. A result labelled “free testosterone” therefore needs its method considered as part of interpretation.
The useful question is not simply whether another test exists. It is whether that test answers a question left open by the total result and whether its method is suitable.
For adult men, the EAU's diagnostic framework combines relevant symptoms and signs with consistently low testosterone. The clinical assessment and the blood tests are considered together. A low number alone does not establish hypogonadism or explain the cause of a man's concerns.
This approach does not assign a particular complaint to every rise or fall in total testosterone. Instead, the clinician assesses whether the symptoms and signs fit the confirmed hormone findings. The total result contributes to that assessment rather than providing a symptom description itself.
The EAU also describes a role for free-testosterone assessment in symptomatic men when SHBG-altering conditions are present. Its guideline notes that this can improve diagnostic accuracy, particularly in older men with obesity. This is a reason to match the measurement to the clinical question rather than assume that every symptom requires the same set of tests.
For related context, understanding why symptoms need blood-test confirmation explains how both parts contribute to an evaluation. It is the relationship between the clinical findings and the laboratory findings that matters.
Total testosterone can vary with circulating SHBG, according to the EAU. Several health conditions and physiological factors may therefore matter when a clinician interprets the total result. The relationships below are associations rather than rules for predicting an individual's hormone levels.
The EAU lists the following among factors associated with reduced SHBG:
Because total testosterone can change with SHBG, a lower total result in this setting does not settle what has happened to the unbound portion. This is why the guideline supports checking SHBG and calculating free testosterone when indicated.
The straightforward example is a lower total result alongside a condition associated with lower SHBG. The next question is whether the free fraction is also low. The total measurement by itself does not separately answer that question.
The EAU lists ageing and hyperthyroidism among factors associated with higher SHBG. Hepatic disease and some medicines are also included. These factors give the clinician reasons to consider how protein binding may affect interpretation.
A higher SHBG level can affect how the total result relates to the free fraction. In that setting, the clinical question may shift from “What is the total?” to “What does this tell us about the unbound portion?” SHBG measurement and an appropriate free-testosterone assessment can help address that question.
These two examples illustrate why the same type of starting test may lead to different follow-up questions. They do not make total testosterone an unsuitable test. The EAU still recommends it as the initial measurement in the diagnostic evaluation.
Testostra's guide to the role of blood carrier proteins gives further context for the distinction between the combined measurement and the free fraction.
The EAU's usual morning window is not a universal clock-time rule for every work schedule. For night-shift workers, the guideline says sampling should follow an adequate sleep period. That distinction belongs in a conversation about how a result was obtained.
Collection conditions and binding proteins concern different parts of interpretation. Timing concerns how the sample was obtained. SHBG concerns how testosterone is carried in blood. Reviewing both helps keep a sampling question separate from a binding-protein question.
The guideline also recommends evaluating diseases and drugs or substances that may interfere with testosterone production or action. A medication and health-history review is therefore part of the wider assessment. This is a reason for clinical review rather than an instruction to change medicines independently.
When evaluation needs to distinguish types of hypogonadism, the EAU recommends luteinising hormone and follicle-stimulating hormone measurements. These are additional parts of the clinical assessment rather than replacements for total testosterone. Their role is to help answer a different question about the underlying hormonal picture.
Ask your physician: “How does my result fit this laboratory's interval and my symptoms? Do the sampling conditions or result justify repeat testing? Could SHBG measurement and an appropriate free testosterone method clarify the picture?”
Moving from a total testosterone number to deciding whether binding proteins need attention requires clear biomarker explanations, which Testostra supplies through its educational coverage. Its articles address confusion about SHBG and the distinction between free and total results while keeping laboratory interpretation separate from personal diagnosis and hormone treatment instructions.
Testostra follows testosterone research, clinical guidance and emerging evidence without turning general information into personal treatment advice.
Send us a question, research idea or topic suggestion. Reader questions help shape future Testostra content.
Contact Testostra